UNITED LAB Initiates Phase III Trials of Triple-Agonist UBT251 for Type 2 Diabetes in China

Bulletin Express09-07

The United Laboratories International Holdings Limited (UNITED LAB) announced that the first participant has been dosed in its Phase III clinical programme for UBT251 Injection, a self-developed Class 1 long-acting GLP-1/GIP/GCG triple-agonist targeting type 2 diabetes.

The Phase III programme, conducted by wholly-owned subsidiary The United Bio-Technology (Hengqing) Co., Ltd., comprises two studies:

1. UNIGUIDE-1: A randomized, double-blind, placebo-controlled trial enrolling 360 adults with HbA1c between 7.5 % and 10.5 %. The primary endpoint is change in HbA1c after 40 weeks of treatment.

2. UNIGUIDE-2: A randomized, open-label study comparing UBT251 with semaglutide injection in 956 adults whose HbA1c ranges from 7.5 % to 11.0 % despite metformin and/or sulfonylureas or SGLT2 inhibitors. The primary endpoint is change in HbA1c at week 40, with secondary endpoints covering body weight, blood pressure, lipid profiles and HbA1c at week 52.

UBT251 is the first chemically synthesised long-acting GLP-1R/GIPR/GCGR triple-agonist to enter clinical trials in China and only the second worldwide. Regulatory clearances have been obtained in China and/or the United States for additional indications, including overweight or obesity, chronic kidney disease, metabolic dysfunction-associated steatohepatitis and obstructive sleep apnoea with obesity.

UNITED LAB and United Bio-Technology signed an exclusive licence agreement with Novo Nordisk A/S for UBT251 in March 2025.

The Board, chaired by Mr Tsoi Hoi Shan, released the update on 7 September 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120940133?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-07 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120940133","market":"hk","top_or_hot":-1,"title":"UNITED LAB Initiates Phase III Trials of Triple-Agonist UBT251 for Type 2 Diabetes in China","media":"Bulletin Express","content":"<p>The United Laboratories International Holdings Limited (UNITED LAB) announced that the first participant has been dosed in its Phase III clinical programme for UBT251 Injection, a self-developed Class 1 long-acting GLP-1/GIP/GCG triple-agonist targeting type 2 diabetes.</p>\n<p>The Phase III programme, conducted by wholly-owned subsidiary The United Bio-Technology (Hengqing) Co., Ltd., comprises two studies:</p>\n<p>1. UNIGUIDE-1: A randomized, double-blind, placebo-controlled trial enrolling 360 adults with HbA1c between 7.5 % and 10.5 %. The primary endpoint is change in HbA1c after 40 weeks of treatment.</p>\n<p>2. UNIGUIDE-2: A randomized, open-label study comparing UBT251 with semaglutide injection in 956 adults whose HbA1c ranges from 7.5 % to 11.0 % despite metformin and/or sulfonylureas or SGLT2 inhibitors. The primary endpoint is change in HbA1c at week 40, with secondary endpoints covering body weight, blood pressure, lipid profiles and HbA1c at week 52.</p>\n<p>UBT251 is the first chemically synthesised long-acting GLP-1R/GIPR/GCGR triple-agonist to enter clinical trials in China and only the second worldwide. Regulatory clearances have been obtained in China and/or the United States for additional indications, including overweight or obesity, chronic kidney disease, metabolic dysfunction-associated steatohepatitis and obstructive sleep apnoea with obesity.</p>\n<p>UNITED LAB and United Bio-Technology signed an exclusive licence agreement with Novo Nordisk A/S for UBT251 in March 2025.</p>\n<p>The Board, chaired by Mr Tsoi Hoi Shan, released the update on 7 September 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB Initiates Phase III Trials of Triple-Agonist UBT251 for Type 2 Diabetes in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB Initiates Phase III Trials of Triple-Agonist UBT251 for Type 2 Diabetes in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-07 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The United Laboratories International Holdings Limited (UNITED LAB) announced that the first participant has been dosed in its Phase III clinical programme for UBT251 Injection, a self-developed Class 1 long-acting GLP-1/GIP/GCG triple-agonist targeting type 2 diabetes.</p>\n<p>The Phase III programme, conducted by wholly-owned subsidiary The United Bio-Technology (Hengqing) Co., Ltd., comprises two studies:</p>\n<p>1. UNIGUIDE-1: A randomized, double-blind, placebo-controlled trial enrolling 360 adults with HbA1c between 7.5 % and 10.5 %. The primary endpoint is change in HbA1c after 40 weeks of treatment.</p>\n<p>2. UNIGUIDE-2: A randomized, open-label study comparing UBT251 with semaglutide injection in 956 adults whose HbA1c ranges from 7.5 % to 11.0 % despite metformin and/or sulfonylureas or SGLT2 inhibitors. The primary endpoint is change in HbA1c at week 40, with secondary endpoints covering body weight, blood pressure, lipid profiles and HbA1c at week 52.</p>\n<p>UBT251 is the first chemically synthesised long-acting GLP-1R/GIPR/GCGR triple-agonist to enter clinical trials in China and only the second worldwide. Regulatory clearances have been obtained in China and/or the United States for additional indications, including overweight or obesity, chronic kidney disease, metabolic dysfunction-associated steatohepatitis and obstructive sleep apnoea with obesity.</p>\n<p>UNITED LAB and United Bio-Technology signed an exclusive licence agreement with Novo Nordisk A/S for UBT251 in March 2025.</p>\n<p>The Board, chaired by Mr Tsoi Hoi Shan, released the update on 7 September 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1120940133","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120940133","pubTimestamp":1788786088,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"The United Laboratories International Holdings Limited (UNITED LAB) announced that the first participant has been dosed in its Phase III clinical programme for UBT251 Injection, a self-developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药"},"translate_title":"联邦制药在中国启动三重激动剂UBT251治疗2型糖尿病的III期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"The United Laboratories International Holdings Limited (UNITED LAB) announced that the first participant has been dosed in its Phase III clinical programme for UBT251 Injection, a self-developed Class 1 long-acting GLP-1/GIP/GCG triple-agonist targeting type 2 diabetes.\nThe Phase III programme, conducted by wholly-owned subsidiary The United Bio-Technology (Hengqing) Co., Ltd., comprises two studies:\n1. UNIGUIDE-1: A randomized, double-blind, placebo-controlled trial enrolling 360 adults with HbA1c between 7.5 % and 10.5 %. The primary endpoint is change in HbA1c after 40 weeks of treatment.\n2. UNIGUIDE-2: A randomized, open-label study comparing UBT251 with semaglutide injection in 956 adults whose HbA1c ranges from 7.5 % to 11.0 % despite metformin and/or sulfonylureas or SGLT2 inhibitors. The primary endpoint is change in HbA1c at week 40, with secondary endpoints covering body weight, blood pressure, lipid profiles and HbA1c at week 52.\nUBT251 is the first chemically synthesised long-acting GLP-1R/GIPR/GCGR triple-agonist to enter clinical trials in China and only the second worldwide. Regulatory clearances have been obtained in China and/or the United States for additional indications, including overweight or obesity, chronic kidney disease, metabolic dysfunction-associated steatohepatitis and obstructive sleep apnoea with obesity.\nUNITED LAB and United Bio-Technology signed an exclusive licence agreement with Novo Nordisk A/S for UBT251 in March 2025.\nThe Board, chaired by Mr Tsoi Hoi Shan, released the update on 7 September 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120940133","isCrawlerRequest":true}